Chiasma advances U.S. commercial launch originally planned for fourth quarter
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the commercial launch and availability of MYCAPSSA® (octreotide) capsules in the United States for patients with acromegaly. MYCAPSSA, the first and only oral somatostatin analog (SSA), was approved by the U.S. Food and Drug Administration (FDA) on June 26, 2020 for the long-term maintenance treatment of patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide.
“I am proud of our employees’ tireless efforts to achieve the earlier-than-expected U.S. commercial launch of MYCAPSSA, the first and only oral SSA in an injectable dominated market,” stated Raj Kannan, chief executive officer of Chiasma. “We are executing on our plan to make MYCAPSSA widely available to potentially address the strong preference by patients with acromegaly for an oral, non-medically administered therapy.”
Anand Varadan, chief commercial officer of Chiasma, commented, “To support our launch of MYCAPSSA in the U.S., we have trained and deployed the first wave of what we believe is a world class sales team experienced in specialty, orphan diseases. Our team has been in the field since late July and we believe it is sized for and possesses the capabilities to operate in the current, predominantly remote environment. We plan to expand our customer-facing team as our commercial launch progresses and as we see the level of in-person interactions with healthcare providers increase. The initial feedback on MYCAPSSA from healthcare providers has been encouraging and we are continuing to engage with them to establish the foundation needed to execute a robust launch of MYCAPSSA.”